Document:

Exhibit 10.53

 

INDEPENDENT DIRECTOR AGREEMENT

 

INDEPENDENT DIRECTOR AGREEMENT
(this “Agreement”), dated ____________, 2022, by and between Marizyme, Inc., a
Nevada corporation (the “Company”), and the undersigned (the “Director”).

 

RECITALS

 

A. The
Company has filed a registration statement on Form S-1 relating to a firm commitment public offering of its securities (the “Offering”).

 

B. The
Company desires the Director to serve on the Company’s board of directors (the “Board”), which may include membership
on one or more committees of the Board, and the Director desires to confirm his or her willingness to serve on the Board.

 

AGREEMENT

 

NOW THEREFORE, in consideration
of the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, and intending to be legally bound
hereby, the Company and the Director hereby agree as follows:

 

1. Duties.
From and after the date hereof (the “Effective Time”), the Company requires that the Director be available to perform
the duties of an independent director customarily related to this function as may be determined and assigned by the Board and as may be
required by the Company’s constituent instruments, including its articles of incorporation and bylaws, as amended, and its corporate
governance and board committee charters, each as amended or modified from time to time, and by applicable law, including the Nevada Revised
Statutes. The Director agrees to devote as much time as is necessary to perform completely the duties as a Director of the Company, including
duties as a member of one or more committees of the Board, to which the Director may have been, or hereafter be, appointed. The Director
will perform such duties described herein in accordance with the general fiduciary duty of directors.

 

2. Term.
The term of this Agreement shall commence as of the Effective Time, and shall continue until the Director’s removal or resignation.

 

3. Compensation.

 

(a) Cash
Compensation. Following the Effective Time and the commencement of the term of this Agreement, for all services to be rendered by
the Director in any capacity hereunder, the Company agrees to compensate the Director a fee of $[*] per year in cash (the “Annual
Fee”), which Annual Fee shall be paid to the Director in four equal installments no later than the fifth business day of each
calendar quarter commencing in the first quarter following the Effective Time. The Director shall be responsible for his or her own individual
income tax payment on the Annual Fee in jurisdictions where the Director resides.

 

(b) Equity
Compensation. Following the Effective Time and the commencement of the term of this Agreement, the Director shall be entitled to receive
an annual award of stock options (the “Award”) to purchase [ ] shares of common stock of the Company. The Award shall
vest in [twelve (12) equal quarterly installments over a one (1)-year period] [twelve (12) equal monthly installments over a three (3)-year
period] commencing in the quarter following the Effective Time as to the initial Award and the date of grant for each subsequent Award.
The Award shall have an exercise price equal to the fair market value per share on the date of grant as determined by the Board, subject
to the Director continuing in service on the Board through each such vesting date.

 

     

     

    

 

4. Independence.
The Director acknowledges that the compensation and expense reimbursements provided hereunder are contingent upon the Board’s determination
that he or she is “independent” with respect to the Company, in accordance with the listing requirements of The Nasdaq Stock
Market LLC and NYSE American, and that his or her compensation and expense reimbursements may be terminated by the Company in the event
that the Director does not maintain such independence standard.

 

5. Expenses.
The Company shall reimburse the Director for pre-approved reasonable business-related expenses incurred in good faith in connection with
the performance of the Director’s duties for the Company. Such reimbursement shall be made by the Company upon submission by the
Director of a signed statement itemizing the expenses incurred, which shall be accompanied by sufficient documentation to support the
expenditures.

 

6. Other
Agreements.

 

(a) Confidential
Information and Insider Trading. The Company and the Director each acknowledge that, in order for the intentions and purposes of this
Agreement to be accomplished, the Director shall necessarily be obtaining access to certain confidential information concerning the Company
and its affairs, including, but not limited to, business methods, information systems, financial data and strategic plans which are unique
assets of the Company (as further defined below, the “Confidential Information”) and that the communication of such
Confidential Information to third parties could irreparably injure the Company and its business. Accordingly, the Director agrees that,
during his or her association with the Company and thereafter, he or she will treat and safeguard as confidential and secret all Confidential
Information received by him or her at any time and that, without the prior written consent of the Company, he or she will not disclose
or reveal any of the Confidential Information to any third party whatsoever or use the same in any manner except in connection with the
business of the Company and in any event in no way harmful to or competitive with the Company or its business. For purposes of this Agreement,
“Confidential Information” includes any information not generally known to the public or recognized as confidential
according to standard industry practice, any trade secrets, know-how, development, manufacturing, marketing and distribution plans and
information, inventions, formulas, methods or processes, whether or not patented or patentable, pricing policies and records of the Company
(and such other information normally understood to be confidential or otherwise designated as such in writing by the Company), all of
which the Director expressly acknowledges and agrees shall be confidential and proprietary information belonging to the Company. Upon
termination of his or her association with the Company, the Director shall return to the Company all documents and papers relating to
the Company, including any Confidential Information, together with any copies thereof, or certify that he or she has destroyed all such
documents and papers. Furthermore, the Director recognizes that the Company has received and in the future will receive confidential or
proprietary information from third parties subject to a duty on the Company’s part to maintain the confidentiality of such information
and, in some cases, to use it only for certain limited purposes. The Director agrees that the Director owes the Company and such third
parties, both during the term of the Director’s association with the Company and thereafter, a duty to hold all such confidential
or proprietary information in the strictest confidence and not to, except as is consistent with the Company’s agreement with the
third party, disclose it to any person or entity or use it for the benefit of anyone other than the Company or such third party, unless
expressly authorized to act otherwise by an officer of the Company. In addition, the Director acknowledges and agrees that the Director
may have access to “material non-public information” for purposes of the federal securities laws (“Insider Information”)
and that the Director will abide by all securities laws relating to the handling of and acting upon such Insider Information.

 

(b) Disparaging
Statements. At all times during and after the period in which the Director is a member of the Board and at all times thereafter, the
Director shall not either verbally, in writing, electronically or otherwise: (i) make any derogatory or disparaging statements about the
Company, any of its affiliates, any of their respective officers, directors, shareholders, employees and agents, or any of the Company’s
current or past customers or employees, or (ii) make any public statement or perform or do any other act prejudicial or injurious to the
reputation or goodwill of the Company or any of its affiliates or otherwise interfere with the business of the Company or any of its affiliates;
provided, however, that nothing in this paragraph shall preclude the Director from complying with all obligations imposed by law or legal
compulsion, and provided, further, however, that nothing in this paragraph shall be deemed applicable to any testimony given by the Director
in any legal or administrative proceedings.

 

    2

     

    

 

(c) Work
Product. The Director agrees that any and all Work Product (as defined below) shall be the Company’s sole and exclusive property.
The Director hereby irrevocably assigns to the Company all right, title and interest worldwide in and to any deliverables resulting from
the Director’s services as a director to the Company (“Deliverables”), and to any ideas, concepts,
processes, discoveries, developments, formulae, information, materials, improvements, designs, artwork, content, software programs, other
copyrightable works, and any other work product created, conceived or developed by you (whether alone or jointly with others) for the
Company during or before the term of this Agreement, including all copyrights, patents, trademarks, trade secrets, and other intellectual
property rights therein (the “Work Product”). The Director retains no rights to use the Work Product and agrees not
to challenge the validity of the Company’s ownership of the Work Product. Director agrees to execute, at the Company’s request
and expense, all documents and other instruments necessary or desirable to confirm such assignment. In the event that the Director does
not, for any reason, execute such documents within a reasonable time after the Company’s request, the Director hereby irrevocably
appoints the Company as the Director’s attorney-in-fact for the purpose of executing such documents on the Director’s behalf,
which appointment is coupled with an interest. The Director will deliver to the Company any Deliverables and disclose promptly in writing
to the Company all other Work Product.

 

(d) Enforcement.
The Director acknowledges and agrees that the covenants contained herein are reasonable, that valid consideration has been and will be
received and that the agreements set forth herein are the result of arms-length negotiations between the parties hereto. The Director
recognizes that the provisions of this Section 6 are vitally important to the continuing welfare of the Company and its affiliates and
that any violation of this Section 6 could result in irreparable harm to the Company and its affiliates for which money damages would
constitute a totally inadequate remedy. Accordingly, in the event of any such violation by the Director, the Company and its affiliates,
in addition to any other remedies they may have, shall have the right to institute and maintain a proceeding to compel specific performance
thereof or to obtain an injunction or other equitable relief restraining any action by the Director in violation of this Section 6 without
posting any bond therefor or demonstrating actual damages, and the Director will not claim as a defense thereto that the Company has an
adequate remedy at law or require the posting of a bond. If any of the restrictions contained in this Section 6 shall for any reason be
held by an arbitrator to be excessively broad as to duration, geographical scope, activity or subject, such restrictions shall be construed
so as thereafter to be limited or reduced to be enforceable to the extent compatible with the applicable law; it being understood that
by the execution of this Agreement the parties hereto regard such restrictions as reasonable and compatible with their respective rights.
The Director acknowledges that injunctive relief may be granted immediately upon the commencement of any such action without notice to
the Director and in addition the Company may recover monetary damages.

 

(e) Separate
Agreement. The parties hereto further agree that the provisions of Section 6 are separate from and independent of the remainder of
this Agreement and that Section 6 is specifically enforceable by the Company notwithstanding any claim made by the Director against the
Company. The terms of this Section 6 shall survive termination of this Agreement.

 

7. Market
Stand-Off Agreement. In the event of a public or private offering of the Company’s securities, including in connection
with the Offering, and upon request of the Company, the underwriters or placement agents placing the offering of the Company’s securities,
the Director agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities
of the Company that the Director may own, other than those included in a registration statement relating to such offering, without the
prior written consent of the Company or such underwriters or placement agents, as the case may be, for such period of time from the effective
date of such registration statement as may be requested by the Company or such placement agent or underwriter.

 

8. Termination.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days’ written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination. Nothing
contained herein or omitted herefrom shall prevent the stockholder(s) of the Company from removing the Director with immediate effect
at any time for any reason. Termination of this Agreement shall not constitute removal of the Director from the Board.

 

    3

     

    

 

9. Indemnification.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Nevada, and
as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the Indemnification
Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in the Director’s
official capacity and as to action in another capacity while holding such office. The Company and the Director are executing an indemnification
agreement in the form attached hereto as Exhibit A.

 

10. Effect
Of Waiver. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.

 

11. Notice.
Any and all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto
or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and Exchange
Commission (“SEC”).

 

12. Governing
Law; Arbitration. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be
determined by, the laws of the State of Florida without reference to that state’s conflicts of laws principles. Any disputes or
claims arising under or in connection with this Agreement or the transactions contemplated hereunder shall be resolved by binding arbitration.
Notice of a demand to arbitrate a dispute by any party hereto shall be given in writing to the other parties hereto at their last known
addresses. Arbitration shall be commenced by the filing by such a party of an arbitration demand with the American Arbitration Association
(“AAA”). The arbitration and resolution of the dispute shall be resolved by a single arbitrator appointed by the AAA
pursuant to AAA rules. The arbitration shall in all respects be governed and conducted by applicable AAA rules, and any award and/or decision
shall be conclusive and binding on the parties. The arbitration shall be conducted in or as near as possible to the Company’s address
as specified in filings made by the Company with the SEC. The arbitrator shall supply a written opinion supporting any award, and judgment
may be entered on the award in any court of competent jurisdiction. Each party hereto shall pay its own fees and expenses for the arbitration,
except that any costs and charges imposed by the AAA and any fees of the arbitrator for his or her services shall be assessed against
the losing party by the arbitrator. In the event that preliminary or permanent injunctive relief is necessary or desirable in order to
prevent a party from acting contrary to this Agreement or to prevent irreparable harm prior to a confirmation of an arbitration award,
then any party hereto is authorized and entitled to commence a lawsuit solely to obtain equitable relief against the other party pending
the completion of the arbitration in a court having jurisdiction over those parties.

 

13. Assignment.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder shall
inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the Director under
this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without the prior written
consent of the Company.

 

14. Miscellaneous.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such invalidity
or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same manner as if the
invalid or illegal provision had not been contained herein. The article headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument.
Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal
ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes. Except as provided elsewhere herein, this Agreement sets
forth the entire agreement of the parties with respect to its subject matter and supersedes all prior agreements, promises, covenants,
arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any
party to this Agreement with respect to such subject matter.

 

[Signature Page Follows]

 

    4

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Independent Director Agreement to be duly executed and signed as of the day and year first above written.

 

	 	COMPANY:
	 	 	 
	 	Marizyme, Inc.
	 	 	 
	 	By:	 
	 	Name:  	David Barthel
	 	Title:	Chief Executive Officer
	 	 	 
	 	DIRECTOR:

 

	 	 
	 	Name:	 
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 

 

     

     

    

 

EXHIBIT A

 

Indemnification Agreement

 

(See Attached)Exhibit
10.55

 

WAIVER

 

This
WAIVER (this “Waiver”) is made and entered into as of July 22, 2022 by and between Marizyme, Inc., a Nevada
corporation (the “Company”) and Viner Total Investments Fund, an entity (the “Investor”).

 

WHEREAS,
pursuant to Section 2.1(a) of the Unit Purchase Agreement, dated as of December 21, 2021 (as amended and in effect from time to time,
including any replacement agreement therefor, the “Purchase Agreement”), among the Company and the Investor, the Investor
agreed to subscribe for $10,000,000 in Units in three tranches. Unless otherwise agreed, three Closings were contemplated: (i) at the
Initial Closing, the Investor agreed to subscribe for $6,000,000 in Units; (ii) upon the Company duly filing of its Registration Statement
on Form S-1, the Investor agreed to subscribe for $2,000,000 in Units; and (iii) upon the Company responding in a satisfactory manner
to the first round of SEC comments, the Investor agreed to subscribe for $2,000,000 in Units.

 

WHEREAS,
on or around December 21, 2021, the Investor invested $6,000,000, and received 3,428,571 Units pursuant to the per-Unit purchase price
under the Purchase Agreement.

 

WHEREAS,
a registration statement on Form S-1 was initially filed by the Company on February 14, 2022; and on February 22, 2022, the Securities
and Exchange Commission issued a letter stating that there would be no review of the registration statement. The Investor has not subscribed
for $2,000,000 in Units as a result of either of the above events.

 

WHEREAS,
the Company and the Investor desire to confirm the Investor’s waiver of any rights to subscribe for any Units pursuant to the Purchase
Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.
Definitions; Transaction Documents. Capitalized terms used herein without definition shall have the meanings assigned to
such terms in the Purchase Agreement. This Waiver shall constitute a waiver for all purposes of the Purchase Agreement under Section
11.9 thereof.

 

2.
Confirmation of Waiver. The Investor hereby confirm its waiver of any rights to subscribe for any Units pursuant to Section
2.1(a)(i) or Section 2.1(a)(ii) of the Purchase Agreement.

 

3.
Conditions to Effectiveness of Waiver. This Waiver shall become effective upon receipt by the Company and the Investor
of counterpart signatures to this Waiver duly executed and delivered by the Company and the Investor.

 

4.
No Implied Consent or Waiver. Except as expressly set forth in this Waiver, this Waiver shall not, by implication or otherwise,
limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Investor under the Purchase Agreement or the
other Transaction Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the
Purchase Agreement or the other Transaction Documents, all of which shall continue in full force and effect. Nothing in this Waiver shall
be construed to imply any willingness on the part of the Investor to agree to or grant any similar or future amendment, consent or waiver
of any of the terms and conditions of the Purchase Agreement or the other Transaction Documents.

 

5.
Counterparts. This Waiver may be executed by the parties hereto in several counterparts, each of which shall be an original
and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart of a signature page of
this Waiver by e-mail (e.g., “pdf” or “tiff”) or fax transmission shall be effective as delivery of a manually
executed counterpart of this Consent.

 

6.
Governing Law. THIS WAIVER SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE
TO CONTRACTS MADE AND TO BE PREPARED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

 

[Remainder
of Page Intentionally Left Blank.]

 

    

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Consent to be executed by their respective officers thereunto duly authorized
as of the day and year first above written.

 

	MARIZYME, INC.	 
	 	 
	By: 	/s/ David Barthel	 
	Name:  	David Barthel	 
	Title: 	Chief Executive Officer	 
	 	 	 
	Viner
    total investments fund	 
	 	 
	By:	 /s/ Cheng Wan Wing	 
	Name: 	Cheng Wan Wing	 
	Title: 	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]